Investigational

Therapies

Our team strives to advance medicines for neurological, neuroendocrine, and neuropsychiatric disorders.

We relentlessly pursue scientific discovery and
development that can lead to important
therapies for patients who desperately need
new, better options.

Movement Disorders

valbenazine* for dyskinetic cerebral palsy (DCP)
Valbenazine* is an investigational, selective vesicular monoamine transporter 2 (VMAT2) inhibitor for the potential treatment of DCP.
Learn More >

Clinical Studies

NBI-98854-DCP3018

KINECT®-DCP
NBI-1076986
NBI-1076986 is an investigational, oral, muscarinic M4 selective acetylcholine antagonist for the potential treatment of certain movement disorders.
Learn More >

Clinical Studies

Ongoing Phase 1 study

Epilepsy

NBI-921352^‡ for SCN8A developmental and epileptic encephalopathy (SCN8A-DEE)
NBI-921352^‡ is an investigational, selective sodium channel inhibitor (Na_v1.6) for the potential treatment of SCN8A-DEE.
Learn More >

Clinical Studies

KAYAK ™

Congenital Adrenal Hyperplasia

crinecerfont for congenital adrenal hyperplasia (CAH)
Crinecerfont is an investigational, oral, nonsteroidal, selective corticotropin-releasing factor type 1 (CRF₁) receptor antagonist for the potential treatment of CAH due to 21-hydroxylase deficiency (21-OHD) in children and adults.
Learn More >

Clinical Studies

CAHtalyst ™ Pediatric

CAHtalyst ™ Adult

Neuropsychiatric Disorders

valbenazine* as an add-on treatment for schizophrenia
Valbenazine is an investigational, selective vesicular monoamine transporter 2 (VMAT2) inhibitor being developed as a potential add-on treatment for patients with schizophrenia.
Learn More >

Clinical Studies

Journey Study
NBI-1065845^§ for inadequate response to treatment in major depressive disorder (MDD)
NBI-1065845^§ is a potential first-in-class, investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) potentiator for the potential treatment of patients with inadequate response to treatment in MDD.
Learn More >

Clinical Studies

Ongoing Phase 2 study
NBI-1117568^¶ for schizophrenia
NBI-1117568^¶ is an oral, investigational muscarinic M4 agonist for the potential treatment of schizophrenia.
Learn More >

Clinical Studies

Phase 2 study
NBI-1070770^§ for major depressive disorder (MDD)
NBI-1070770, an investigational, oral, negative allosteric modulator (NAM) of the NR2B subunit-containing N-methyl-D-aspartate receptor (NR2B-NMDAR) as a potential treatment for major depressive disorder.
Learn More >

Clinical Studies

Ongoing Phase 2 study
NBI-1117570^¶
NBI-1117570 is an investigational, oral, muscarinic M1/M4 agonist being developed for the potential treatment of certain neurological and neuropsychiatric conditions.
Learn More >

Clinical Studies

Ongoing Phase 1 study
NBI-1117569^¶
NBI-1117569 is an investigational, oral, muscarinic M1/M4 (M4 preferring) acetylcholine agonist for the potential treatment of certain neurological and neuropsychiatric conditions.
Learn More >

Clinical Studies

Ongoing Phase 1 study
NBI-1117567^¶
NBI-1117567 is an investigational, oral, muscarinic M1/M4 (M1 preferring) acetylcholine agonist for the potential treatment of certain neurological and neuropsychiatric conditions.
Learn More >

Clinical Studies

Ongoing Phase 1 study
NBI-1065890
NBI-1065890 is an investigational, oral, selective inhibitor of vesicular monoamine transporter-2 (VMAT2) being developed as a potential treatment for certain neurological and neuropsychiatric conditions.
Learn More >

Clinical Studies

Ongoing Phase 1 study

Neurocrine Biosciences has global rights unless otherwise noted. Neurocrine Biosciences shares profits and losses on NBI-1065845 with Takeda Pharmaceutical Company Limited.
_^*Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Japan and other select Asian markets.
^‡Licensed from Xenon Pharmaceuticals, Inc.
^§Licensed from Takeda Pharmaceutical Company Limited.
^¶Licensed from Nxera Pharma (formerly Sosei Heptares).

Our Approved Medicines

Take a Closer Look

Investor

Information

Learn More

Investigational

Therapies

We relentlessly pursue scientific discovery and
development that can lead to important
therapies for patients who desperately need
new, better options.

Movement Disorders

valbenazine* for dyskinetic cerebral palsy (DCP)

Clinical Studies

NBI-1076986

Clinical Studies

Epilepsy

NBI-921352^‡ for SCN8A developmental and epileptic encephalopathy (SCN8A-DEE)

Clinical Studies

Congenital Adrenal Hyperplasia

crinecerfont for congenital adrenal hyperplasia (CAH)

Clinical Studies

Neuropsychiatric Disorders

valbenazine* as an add-on treatment for schizophrenia

Clinical Studies

NBI-1065845^§ for inadequate response to treatment in major depressive disorder (MDD)

Clinical Studies

NBI-1117568^¶ for schizophrenia

Clinical Studies

NBI-1070770^§ for major depressive disorder (MDD)

Clinical Studies

NBI-1117570^¶

Clinical Studies

NBI-1117569^¶

Clinical Studies

NBI-1117567^¶

Clinical Studies

NBI-1065890

Clinical Studies

InvestigationalTherapies

We relentlessly pursue scientific discovery and development that can lead to important therapies for patients who desperately need new, better options.

Movement Disorders

valbenazine* for dyskinetic cerebral palsy (DCP)

Clinical Studies

NBI-1076986

Clinical Studies

Epilepsy

NBI-921352‡ for SCN8A developmental and epileptic encephalopathy (SCN8A-DEE)

Clinical Studies

Congenital Adrenal Hyperplasia

crinecerfont for congenital adrenal hyperplasia (CAH)

Clinical Studies

Neuropsychiatric Disorders

valbenazine* as an add-on treatment for schizophrenia

Clinical Studies

NBI-1065845§ for inadequate response to treatment in major depressive disorder (MDD)

Clinical Studies

NBI-1117568¶ for schizophrenia

Clinical Studies

NBI-1070770§ for major depressive disorder (MDD)

Clinical Studies

NBI-1117570¶

Clinical Studies

NBI-1117569¶

Clinical Studies

NBI-1117567¶

Clinical Studies

NBI-1065890

Clinical Studies

You are leaving Neurocrine.com

Investigational

Therapies

We relentlessly pursue scientific discovery and
development that can lead to important
therapies for patients who desperately need
new, better options.

NBI-921352^‡ for SCN8A developmental and epileptic encephalopathy (SCN8A-DEE)

NBI-1065845^§ for inadequate response to treatment in major depressive disorder (MDD)

NBI-1117568^¶ for schizophrenia

NBI-1070770^§ for major depressive disorder (MDD)

NBI-1117570^¶

NBI-1117569^¶

NBI-1117567^¶